DermaDeep Injection — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

DermaDeep is a cross-linked hyaluronic acid (HA) injectable filler formulated for placement in the deep dermis and subcutaneous tissue planes, where it restores facial volume, corrects deep static folds, and redefines facial contour. Hyaluronic acid is a naturally occurring polysaccharide that attracts and retains water, providing hydration and mechanical support to the extracellular matrix. Cross-linking the HA chains with BDDE (butanediol diglycidyl ether) creates a gel of higher viscosity and longer durability than non-cross-linked HA, resisting enzymatic breakdown for 12–18 months. DermaDeep belongs to the non-animal stabilised hyaluronic acid (NASHA) filler family, sourced through bacterial fermentation, eliminating the need for skin testing. Its rheological properties — G prime (stiffness) and cohesivity — are optimised for the deep injection plane to provide structural lifting without superficial palpability. It is commonly used for deep nasolabial folds, marionette lines, jowl softening, cheek and temporal volumisation, and selected lip augmentation applications. It is reversible with hyaluronidase enzyme injections at any time. DermaDeep is typically used for deep nasolabial folds, marionette lines, chin augmentation, and cheek volumisation. It is injected using either a cannula or needle technique by aesthetic physicians, dermatologists, or plastic surgeons trained in facial anatomy and filler injection.

DermaDeep injection is indicated for adults aged 25–70 years experiencing moderate to significant facial volume loss and deep static rhytids (wrinkles present at rest) that do not improve with superficial or medium-depth injectable treatments. Key indications include deep nasolabial folds (the lines running from nose corners to mouth corners) causing a fatigued or aged appearance, marionette lines extending from the corners of the mouth downward, moderate jowl formation from midfacial volume loss, hollow temporal regions, and deflated cheeks resulting from subcutaneous fat pad ptosis and loss associated with ageing, weight loss, or lipodystrophy. It is also used for lip augmentation in patients seeking structural volume rather than superficial hydration. Ideal candidates are non-smokers (or willing to reduce) with good general health, realistic expectations about non-surgical rejuvenation, and no recent herpes labialis outbreak at planned treatment sites. Contraindications include pregnancy and breastfeeding, active skin infection or inflammation at injection sites, known hypersensitivity to hyaluronic acid or bacterial proteins, untreated bleeding disorders, and prior permanent fillers in the same anatomical area without specialist assessment.

Before treatment, a comprehensive facial aesthetic assessment is performed including analysis of facial proportions, skin quality, pre-existing asymmetry, and photographic documentation. Informed consent covering risks, expected outcomes, longevity, and reversal options is obtained. A topical anaesthetic cream (EMLA or similar) is applied for 20–30 minutes, or local anaesthetic blocks (dental nerve blocks, infraorbital nerve blocks) are administered for more comfortable deep injections. DermaDeep contains pre-incorporated lidocaine in most formulations, further reducing procedural discomfort. The injector uses either a sharp 25-gauge needle for depot injections at discrete deep planes, or a blunt cannula for linear threading and retrograde injection techniques that reduce bruising and vascular injury risk. Filler is deposited in small boluses or threads at the supraperiosteal, submuscular, or deep subcutaneous level depending on the target area and desired correction. Volume is incrementally assessed with the patient upright; gentle massage distributes product evenly and checks for smooth contour integration. Treatment of an entire face typically uses 1–3 syringes (1 mL each). The session lasts 30–60 minutes. Ice is applied immediately after to reduce oedema. The total treatment session, including consultation and injection, takes approximately 30–60 minutes. Patients are reviewed at 2–4 weeks to assess the result and determine whether a top-up is required to optimise the outcome.

DermaDeep provides immediate visible volumisation and fold correction with results that improve progressively over 2 weeks as initial oedema subsides and the product integrates into surrounding tissue. Clinical studies demonstrate patient satisfaction rates exceeding 85% at 6 months for deep fold correction. Duration of effect ranges from 12–18 months depending on the anatomical site, volume injected, individual metabolism, and lifestyle factors. Areas with less movement (cheeks, temples) tend to sustain results longer than the perioral region, which undergoes more dynamic stress from speaking and eating. The product is fully reversible — hyaluronidase enzyme injections dissolve the filler within hours, providing a safety advantage unique to HA fillers compared with calcium hydroxylapatite or poly-L-lactic acid fillers. Compared with surgical procedures (facelift, fat grafting), DermaDeep offers no downtime, no surgical scars, and immediate return to social activities, making it the preferred first-line treatment for patients not yet ready for surgery or seeking maintenance between procedures.

Common side effects of DermaDeep injection are mild and transient: bruising at injection sites (resolved within 7–14 days), localised swelling peaking at 24–48 hours and resolving within 5–7 days, and temporary tenderness or redness. These are expected outcomes of the injection process. Uncommon but important complications include nodule formation from filler migration or over-correction, particularly in superficially placed product; this is managed with hyaluronidase or massage. The Tyndall effect — a bluish discolouration visible through thin skin — occurs when HA is placed too superficially in the periorbital area. Infection presenting as delayed-onset nodules weeks to months after injection may represent biofilm formation; treatment involves aspiration, antibiotics, and hyaluronidase. The most serious complication is vascular occlusion from inadvertent intra-arterial injection or external compression of vessels, causing skin ischaemia or, rarely, vision loss from retinal artery embolism. This is a medical emergency requiring immediate high-dose hyaluronidase injection, aspirin, nitroglycerin paste, and emergency ophthalmology consultation. Practitioners must be trained in vascular complication recognition and management, and hyaluronidase must be immediately available in all treatment settings.

No downtime is required after DermaDeep injection — patients can return to work and social activities the same day in most cases, though social engagements on the day of treatment are not recommended due to potential bruising or swelling. Post-procedure instructions include avoiding strenuous exercise for 24 hours (to reduce oedema), avoiding alcohol for 24 hours, avoiding extreme heat (saunas, hot yoga, steam rooms) for 48 hours, and refraining from facial massage or pressure on treated areas for 24 hours to prevent filler displacement. SPF 30+ sun protection is recommended daily as UV exposure can degrade HA. Arnica supplements or topical arnica may reduce bruising. Initial results are visible immediately; final assessment of correction and symmetry is performed at 2 weeks, at which point a top-up treatment can be administered if additional volume is required. Results typically last 12–18 months, after which a maintenance injection restores the original correction. Patients should contact their injector promptly if they notice blanching, pain out of proportion to the procedure, or any visual symptoms, as these may indicate vascular compromise.